Durvalumab extends survival in SCLC but cost-effectiveness questioned
Durvalumab extends survival in small cell lung cancer while raising critical cost-effectiveness concerns. Researchers at the Sylvester Comprehensive…
Browsing Tag
ADRIATIC clinical trial
1 post